Prescient Therapeutics : March 2022 Quarterly Update and Appendix 4C

March 2022 Quarterly Update and Appendix 4C

HIGHLIGHTS:

•  Strong cash position of $13.13 million to support cancer therapy programs

•  Recruitment open for expanded cohort of Phase 1b PTX-100 study

•  Solid progress on Cell Therapy Enhancement and OmniCAR programs

•  Ongoing engagement with medical and investment community to build awareness

MELBOURNE Australia, 29 April 2022 - Prescient Therapeutics (ASX: PTX), a clinical-stage oncology company developing personalised therapies for cancer, today reported its March 2022 quarterly results and operating highlights.

Prescient made progress across multiple programs in its diverse and differentiated oncology portfolio. Moreover, the Company remains confident in the potential of its programs, which continue to progress and attract the attention of leaders and innovators across the international oncology community.

Strong financial position

Prescient ended the quarter with a cash balance of $13.12 million. Costs for the quarter included ongoing clinical trials and manufacturing for PTX-100 and PTX-200 as well as development of the OmniCAR next-generation CAR-T platform. Total cash outflows were $1.63 million, including $1.07 million invested in research and development. Payments during the quarter to related parties of the entity and their associates were $284,000. These payments are related to executive director remuneration and superannuation and non-executive director fees. Full details are in the attached Appendix 4C for the March 2022 quarter.

OmniCAR continues to advance

Prescient's OmniCAR is a next-generation cell therapy platform created to address the shortcomings of current-generation CAR-T, by creating cell therapies that able to target multiple cancer antigens simultaneously or sequentially, can be controlled post infusion, and can accommodate any cancer targeting binder (to target a variety of cancers), and any immune cell type. OmniCAR incorporates technology licensed from the pioneers of CAR-T at the University of Pennsylvania, as well as Oxford University.

Solid progress has been made on the OmniCAR platform during the quarter. Current pre-clinical work is focused on three programs: acute myeloid leukemia (AML), Her2 positive solid cancers and glioblastoma multiforme (GMB), an aggressive form of brain cancer. Each of these are highly differentiated and use OmniCAR's unique capabilities to create CAR-T therapies to overcome

challenges faced by other CAR-T therapies. Prescient looks forward to providing detailed and specific updates for each of these highly promising programs in coming quarters. Additionally, Prescient has been regularly presenting OmniCAR at international conferences, where the platform has the potential to accommodate and enhance third party assets.

PTX-100 and PTX-200 recruitment progressing

In early April, the expansion cohort in T-cell lymphomas began screening patients under the leadership of Australia's foremost haematologist, Professor Miles Prince AM, following delivery of newly manufactured drug product from the US.

This expansion cohort will enrol throughout the year with the potential for an interim readout in coming quarters. Medical researchers believe further encouraging responses in this patient population could enable a subsequent registration study and a much shorter path to market in order to help a patient population with almost no current options.

Also during the quarter, the study for PTX-200 in patients with acute myeloid leukemia continued to advance in dose escalation. Three patients in the study with advanced forms of this deadly disease have experienced complete responses to date.

Collaboration with the Peter MacCallum Cancer Centre

Prescient's Cell Therapy Enhancements (CTE) program is an ongoing collaboration with the world-renowned Peter MacCallum Cancer Centre aimed at improving the efficiency and efficacy of the current-generation of CAR-T treatments. The insights generated will also be directly applicable to the next-generation CAR-T treatments Prescient is developing.

There has been substantial progress on the CTE program during the quarter. Whilst this program is currently in stealth mode for commercial reasons, Prescient looks forward to revealing details of the CTE program shortly.

Maintaining a positive outlook

Prescient extends appreciation to all shareholders for their ongoing support. Management and the Board acknowledge the turbulent market backdrop, but remain highly focused and confident in the Company's direction and prospects to deliver both value for shareholders and real improvements in the options available for doctors to treat cancer patients.

- Ends -

To stay updated with the latest company news and announcements,please update your details on our investor centre.

About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

Cell Therapies

OmniCAR: is a universal immune receptor platform enabling controllable T-cell activity and multi- antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post- translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens. OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

Prescient is developing OmniCAR programs for next-generation CAR-T therapies for Acute Myeloid Leukemia (AML); Her2+ solid tumours, including breast, ovarian and gastric cancers; and glioblastoma multiforme (GBM).

Cell Therapy Enhancements: Prescient has several other initiatives underway to develop new cell therapy approaches.

Targeted Therapies

PTX-100 is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX- 100 is believed to be the only GGT-1 inhibitor in the world in clinical development. PTX-100 demonstrated safety and early clinical activity in a previous Phase 1 study and recent PK/PD basket study of hematological and solid malignancies. PTX-100 is now in a Phase 1b expansion cohort study in T cell lymphomas.

PTX-200 is a novel PH domain inhibitor that inhibits an important tumour survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition, PTX-200 has a novel mechanism of action that specifically inhibits Akt without non-specific kinase inhibition effects. This highly promising compound has previously generated encouraging Phase 2a data in HER2-negative breast cancer and Phase 1b in recurrent or persistent platinum resistant ovarian cancer, with a Phase 1b/2 trial currently underway in relapsed and refractory AML.

The Board of Prescient Therapeutics Limited has approved the release of this announcement.

Find out more atwww.ptxtherapeutics.com or connect with us via Twitter@PTX_AUS andLinkedIn.

Steven Yatomi-Clarke	Investor enquiries:	Media enquiries:
CEO & Managing Director	Sophie Bradley - Reach Markets	Andrew Geddes - CityPR
Prescient Therapeutics	[phone]	[phone]
[e-mail]	[e-mail]	[e-mail]

Disclaimer and Safe Harbor Statement

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, global pandemics and related disruptions, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. In particular, there are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward- looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward- looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.

Supplemental COVID-19 Risk Factors

Please see our website :Supplemental COVID-19 Risk Factors

Rule 4.7B

Appendix 4C

1.	Cash flows from operating activities
1.1	Receipts from customers	-	-
1.2	Payments for
(a) research and development	(1,072)	(2,681)
(b) product manufacturing and operating	-
costs
(c) advertising and marketing	-	-
(d) leased assets	-	-
(e) staff costs	(340)	(812)
(f) administration and corporate costs	(279)	(1,118)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	9	19
1.5	Interest and other costs of finance paid	(1)	(7)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	50	1,376
1.8	Other (provide details if material)	-	-
1.9	Net cash from / (used in) operating
activities	(1,633)	(3,223)
2.	Cash flows from investing activities
2.1	Payments to acquire or for:
-	-
-	-
-	-
-	-
-	-
-	-

0BName of entity

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Prescient Therapeutics Limited 1BABN

56 006 569 106

2BQuarter ended ("current quarter")

31 March 2022

3BConsolidated statement of cash flows

• (a) entities

• (b) businesses

• (c) property, plant and equipment

• (d) investments

• (e) intellectual property

• (f) other non-current assets

Current quarter

$A'000

Year to date (9 months) $A'000

ASX Listing Rules Appendix 4C (17/07/20)

+ See chapter 19 of the ASX Listing Rules for defined terms.

Page 1